3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Lung Neoplasms
9
Carcinoma, Hepatocellular
9
Small Cell Lung Carcinoma
8
Breast Neoplasms
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Neoplasms
5
Neoplasm Metastasis
5
Melanoma
5
Glioblastoma
5
Carcinoma, Transitional Cell
5
Ovarian Neoplasms
4
Advanced Solid Tumor
4
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Sarcoma
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Follicular
3
Liver Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Neuroendocrine
3
Solid Cancer
2
Small Cell Lung Cancer Extensive Stage
2
Recurrence
2
Neuroendocrine Tumors
2
Lymphoma, Large B-Cell, Diffuse
2
Interventions
Pemetrexed
7
Cisplatin
7
Cyclophosphamide
5
pembrolizumab
4
fludarabine
4
Platinum
3
Drug Therapy
3
aldesleukin
2
Nivolumab
2
Ipilimumab
2
Interleukin-2
2
1,2-diaminocyclohexaneplatinum II citrate
2
vatalanib
1
spartalizumab
1
regorafenib
1
napabucasin
1
methoxyamine
1
fludarabine phosphate
1
enzalutamide
1
cediranib
1
avelumab
1
atezolizumab
1
anetumab ravtansine
1
Vorinostat
1
Thiostrepton
1
Tetrahydrouridine
1
Radiosurgery
1
Megestrol Acetate
1
Levoleucovorin
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Mesothelioma, Malignant
×
atezolizumab
×
Clear all
NCT05765084
2024-05-16
Immuno-MESODEC
University Hospital, Antwerp
Phase 1/2
Recruiting
15 enrolled